Michelle Deaker’s OneVentures, widely regarded as one of Australia’s shrewdest venture capital investors, is gearing up to raise a new healthcare-focused fund later this year. However, the effort won’t be without prospective investors questioning the exit status at its biggest moneymakers, including the $1.3 billion vaccine patch start-up Vaxxas and the $450 million analytics software player Phocas.

The venture capital investor has told its backers it expects to launch a dedicated healthcare fund in the December quarter, once it has wrapped up the $250 million raising it kicked off for its Growth Fund VII in August.

Loading...